

INDEX

- AAG, 135, 138, 141, 142, 149, 151–153, 155–158
- ABC transporter, 40, 43, 48
- academia, 2, 77
- acetaminophen, 66, 68, 74, 95, 114, 121, 130
- active ingredient, 5
- active metabolite, 24, 25, 35, 36, 69, 82, 86, 113, 114, 115, 118, 119–122, 124, 130, 244
- acute effect, 3
- acute renal failure, 47, 48
- acyl glucuronide, 114, 115, 117
- adenosine triphosphate (ATP), 26, 40, 42, 46, 121, 122
- ADME, 2, 5, 12, 13, 31, 32, 56, 86, 88, 89, 91, 93, 97, 109–112, 127, 222
- ADMET, 13
- ADME-Tox model, 109, 112
- AhR. *See* aryl hydrocarbon receptor
- AhRE, 88, 89
- albumin, 22, 23, 138–142, 145, 146, 151, 153, 155–160
- Aldendronate sodium, 198–199, 214
- allometric scaling, 32, 159, 171, 172, 174–176, 181, 182, 240
- alpha-1 acid glycoprotein, 138, 139, 141
- ambient-storage condition, 207
- Ames test, 228, 229
- amino acid sequence, 41, 59, 88, 256
- amiodarone, 68, 267
- amorphous forms, 190–193, 205, 206, 209, 213
- amprenavir, 155
- analgesic, 4, 154
- animal model, 32, 47, 49, 182, 221, 224, 238
- animal species, 27, 56, 60, 123, 156, 171–174, 176, 212, 227, 242
- antibiotics, 4, 49, 69, 76, 77, 93, 142, 143, 176, 226, 268, 269
- anti-cancer compounds, 48, 155, 158, 160, 161
- anticoagulants, 66, 95, 136, 153
- anticonvulsants, 4, 62, 66, 67, 95
- antifungal agents, 69, 75, 76
- anti-HIV compounds, 155
- antimalarials, 142, 172
- antimicrobials, 154, 155
- appropriate species, 223, 237, 271
- area under the curve (AUC), 17, 18, 20, 21, 26, 29, 31, 32, 34, 36, 76–84, 95, 160, 181, 182, 241, 243
- ARF, 47, 48, 50
- arrhythmia, 75, 76, 123, 233, 234, 254, 265, 268, 270, 271, 273
- arrhythmogenic, 265–267, 270, 271
- artificial membrane permeability, 199
- aryl hydrocarbon receptor (AhR), 87

- ASBT, 40
 ATP. *See* adenosine triphosphate
 attrition, 1, 2, 110, 113, 131, 188, 189, 211, 214, 222, 224, 227, 235, 244–246, 248
 autoinduction, 93, 124
- barbiturates, 62, 66, 94
 barrier function, 40
 BCRP. *See* breast cancer resistance protein
 benzodiazepine, 140
 benzphetamine, 68
 bergamottin, 69
 bilateral ureteral obstruction (BUO), 47, 50
 bile acid transporter, 40
 bile/biliary duct, 19, 26
 bile salts, 195
 biliary secretion, 25–27, 30, 174
 binding affinity, 84, 90, 138, 156, 256, 257, 260, 262
 binding site, 15, 23, 26, 42, 43, 45, 61, 66, 73, 88, 89, 138, 140, 141, 142, 153, 258, 259
 bioactivation, 113, 115, 117, 118, 121, 122, 124
 biologic effect, 3
 biomarkers, 156, 223, 226, 237, 240, 244, 246, 247, 254
 biotechnology, 2, 224, 228
 biotransformation, 23, 56, 58, 76, 110
 β -lactam, 49, 143
 blood concentration, 21, 178
 blood-brain barrier, 4, 40, 48, 156, 199
 body weight, 32, 94, 158, 171–174, 182
 bottleneck, 5, 193, 233, 234
 bound fraction, 17, 22, 23, 27, 28, 31, 35, 36, 137, 138, 143, 144–149, 152, 154, 156, 159, 160, 179
 brain penetration, 4
 brain weight, 173
 breast cancer resistance protein (BCRP), 40, 43, 48, 49
 bretylium tosylate, 153
 brush border, 26
 BSEP, 40, 46
 bufuralolol, 68, 72
 BUO. *See* bilateral ureteral obstruction
- Caco-2, 199, 200, 212
 caffeine, 66, 72–74, 94
 canalicular transport protein, 46
 candidate selection, 110, 111, 131, 187, 189, 211, 213
 capillary, 26, 145, 146
 CAR, 88, 90, 91
 carbamazepine, 68, 83, 90, 92, 93, 95, 96, 114
 cardiotoxicity, 76, 113, 157, 262
 cardiovascular toxicology, 3
 catalytic cycle, 55, 57, 58
 cavity, 18, 61, 66, 256, 257
 cefixoxime, 176
 cefmenoxime, 176
 cefodizime, 155, 176
 cefotetan, 176
 cefpirome, 155
 cell or cellular membrane, 13, 22, 23, 43, 47, 198, 199, 262, 264
 cellular structure, 178
 central compartment, 17, 21
 central nervous system (CNS), 4, 48, 68, 154, 156, 241
 centrifugal force, 149–151
 cephaloridine, 49
 cetirizine, 130
 charge-charge interaction, 142
 Chinese Hamster Ovary (CHO), 45, 228, 231, 264
 chronological time, 176
 cimetidine, 77
 citric acid, 153
 clarithromycin, 76, 83, 86, 123, 267, 269, 270
 clastogenicity, 222, 228, 231, 237, 238
 clinical implication, 2, 39, 45, 49
 clinical trial, 2, 3, 5, 112, 113, 156, 170, 181, 182, 228, 233
 Cl_{int} , 78, 144, 146, 159, 160, 177–180
 clotrimazole, 69, 91–93, 95
 C_{max} , 20, 21, 29, 32, 81, 82, 195, 232, 241, 244, 268, 269
 CNS. *See* central nervous system
 CNT, 40
 coadministration, 48, 49, 75
 cocrystals, 187, 195, 208–210
 collaboration, 6, 111

- combination, 4, 17, 21, 34, 77, 123, 124, 207, 224, 263
 compartmental model, 15–17, 176
 concentration-response, 270
 conformational change, 43, 61, 145
 conjugation, 24, 116
 constitutive androstane receptor, 88
 correlation coefficient, 172, 174, 175
 corticotropin-releasing factor, 156
 Cos-7 cell, 43, 47
 CRF, 156
 CRO, 6
 cross-reactivity, 223, 227, 228, 242
 cross-talk, 90, 91
 crystal structure, 61, 62, 68, 90, 140, 226, 255
 crystallinity, 188, 191, 193, 205–206, 212
 crystallographic studies, 140, 190
 cyclodextrin, 195
 cyp enzyme abundance, 55, 60
 CYP1A1, 24, 60, 87–89, 94
 CYP1A2, 57, 60, 64–66, 70, 74, 81, 87, 92–94, 122, 127
 CYP2C19, 57, 60, 62, 64, 67, 73, 122, 131
 CYP2C8, 60, 62, 64, 94
 CYP2C9, 57, 60, 61, 66, 67, 70, 73, 80, 81, 92–94, 122
 CYP2D6, 57, 60, 61, 62, 64, 65, 68, 70, 72, 73, 80, 81, 92, 93, 122
 CYP3A4, 57, 59–65, 68–77, 80, 81, 83, 84, 88–96, 122–124
 cytochrome b5, 58, 59, 70
 cytochrome P450, 4, 23, 25, 55–60, 63, 70, 96, 97, 157, 177, 178, 243

 DAD UV detector, 201
 debrisoquine, 68, 72
 depolarization, 225, 254, 260, 261, 267, 268
 desimipramine, 68
 desloratadine, 130
 developability, 3, 110, 111, 121, 125, 127, 130, 170, 180, 181, 187, 188, 191, 200, 203–205, 211, 213, 214, 235
 dextromethorphan, 62, 64, 65, 68, 72, 73
 dialyzing medium, 147
 diazepam, 62, 64, 67, 68, 73, 95, 139, 140, 156, 271
 diclofenac, 66, 67, 73, 114

 differential scanning calorimetry (DSC), 205–207, 212
 digoxin, 68
 dihydroxyberamottin, 69
 diode-array (DAD), 201
 disintegration, 19, 20
 dispersion model, 179
 displacement, 136, 137, 159, 160, 258–261
 dissociation constant, 138, 196–197
 dissolution rate, 187, 189–191, 196, 204
 distal tubules, 25, 26
 DMPK, 6
 DNA, 12, 59, 65, 88, 90, 228, 229, 239
 dofetilide, 253, 254, 258–262, 268, 272
 dofetilide binding, 259
 drug development, 1, 28, 34, 65, 110, 125, 137, 138, 170, 177, 210, 213, 214, 224, 226, 231, 235, 248, 270, 271.
See also drug discovery and development
 drug discovery and development, 1, 56, 84, 97, 109, 111–113, 118, 135, 137, 170, 235
 drug exposure, 3, 123
 drug metabolizing enzyme, 24, 31, 55, 60, 64, 78, 86, 97, 125, 175, 180
 drug substance, 3, 4, 225
 drug transporter, 39–45, 47–50, 175
 drug–drug interaction, 4, 39, 48–50, 55, 57, 60–62, 69, 74, 75–81, 84, 96, 109, 111, 122–124, 157
 drug-protein complex, 137, 144, 152
 drug-receptor interaction, 12
 duodenum, 20, 26
 dynamic vapor sorption, 205, 207

 efflux pump, 42, 124
 elacridar, 49
 electrochemical gradient, 147, 148
 electrophysiology, 226, 234, 256, 259, 261–264
 elimination, 2, 13–15, 18, 21, 23, 25, 28, 29, 32, 35, 37, 39, 46–49, 56, 60, 136, 174–176, 178, 181, 222
 embryonic stem cells, 236
 empirical guidance, 84
 endocrine, 1, 12
 endoplasmic reticulum (ER), 41, 44, 56, 57, 60

- ENT, 40
 enterocytes, 19, 20, 30
 enterohepatic recycling, 27
 enzyme induction, 55, 56, 87, 96, 124, 126
 enzyme inhibition, 75, 112, 122, 124, 243
 epoxide, 63, 114, 116, 117
 equilibrium dialysis, 22, 146–152, 156
 erythromycin, 68, 69, 72, 73, 76, 83, 86, 123, 267, 269–272
 expenditures, 1, 222, 248
 experimental toxicology, 2
 exponent, 171–175
 extensive metabolizer, 67, 94
 extraction ratio, 11, 27, 28, 30, 144, 146
 extrapolation, 71, 78, 172, 175, 176, 192, 243, 247
- FDA.** *See* U.S. Food and Drug Administration
 fenestration, 25
 ferredoxin, 59
 fexofenadine, 90, 93, 130, 269
 first in human (FIH)/first time in human (FTIH), 169, 170, 175, 181, 227, 228
 first-order elimination, 14, 178
 first-pass metabolism, 24
 flavin mononucleotide, 59
 flip-flop phenomenon, 18, 37
 fluorescence, 71, 92, 93, 123, 135, 150–152, 234, 260–262, 264
 fluorescent analogs, 151
 fluorescent assay, 260
 fluorometric imaging plate readers (FLIPR), 260, 264
 fluvoxamine, 56, 67
 food effect, 189
 Forsamax, 198, 214
 free fraction, 138, 158, 160, 179
 FTIH. *See* first in human/first time in human
 furanocoumarins, 69
- gall bladder, 26
 gastrointestinal (GI) tract, 19, 24, 30, 34, 75, 124, 193, 194, 199, 211, 212, 213, 222, 247
 motility and peristalsis, 19
- gene expression, 41, 233, 237
 genetic toxicity, 113
 genetic toxicology, 228
 genotoxicity, 223–225, 228, 229, 237
 GF120918, 49
 globulin, 22, 23
 glomerular filtration, 25, 32, 145
 glucuronic acid, 116, 117
 glutathione conjugate, 119, 120
 glycoprotein, 20, 22, 23, 26, 34, 41, 42, 95, 135, 138, 139, 141, 199
 glycosylation, 41, 42
 grapefruit juice, 69
 guinea pigs, 258, 266, 267, 271–273
 GV196771, 49
- half-life, 4, 18, 21, 30, 33, 34, 124, 125, 128, 129, 131, 139, 143, 155, 156, 177
 HAS. *See* human serum albumin
 HDL. *See* high-density lipoproteins
 heart, 16, 24, 30, 49, 75, 138, 244, 266, 267, 271, 273
 hepatic artery, 79, 179
 hepatic blood flow, 27, 28, 30, 34, 144, 177, 179
 hepatic clearance, 11, 27, 28, 34, 36, 95, 144, 145, 178, 198
 hepatic metabolism, 176, 181
 hepatic toxicity, 113
 hepatic vein, 19, 27
 hepatobiliary transport, 46
 hepatocytes, 26, 70–72, 87, 91, 93, 119, 120, 124, 126, 139, 157, 159, 177–180, 246
 hepatotoxicity, 95, 114, 117, 124, 222, 223, 232, 233
 HepG2, 91, 124
 hERG. *See* human ether a go-go related gene
 high-density lipoproteins (HDL), 142
 high-throughput screen, 4, 73, 126, 203, 261
 histone deacetylase inhibitor, 156
 HIV, 4, 69, 141, 155
 hot-stage optical microscopy, 205, 207
 HPLC, 73, 74, 123, 192, 198, 201, 212

- human ether a go-go related gene (hERG), 225
 channel, 226, 234, 254–264
 inhibition, 255, 259, 265
- human serum albumin (HAS), 140, 141
- hydrogen bond, 68, 200, 256, 257
- hydroperoxy complex, 58
- hydroxylation, 63, 67, 73
- hygroscopicity, 188, 207, 209, 212
- ibuprofen, 66, 139, 140
- ileum, 20
- imatinib, 139, 155, 156, 158, 160
- imipramine, 22, 66–68
- in silico*, 109, 111, 112, 125–127, 131, 176, 198, 221, 223–226, 234, 248, 253, 255–258
- in situ* salt formation, 197
- in vitro* screening, 55, 70, 91, 233
- in vivo* probe, 66–69
- inactivation, 69, 82–86, 127, 261, 262, 265
- indinavir, 68, 95
- induction rate, 273
- infectious disease, 1
- interindividual variability, 41, 45, 62, 158, 180
- internalization, 43
- interspecies scaling, 32
- intestinal tissue, 12
- intestinal tract, 18, 20. *See also* GI tract
- intramuscular, 12, 18
- intravenous route, 4, 12, 18, 37, 142, 159, 172, 196, 267, 271
- intrinsic clearance, 27, 28, 36, 78, 144, 146, 159, 177, 178, 180, 181
- intrinsic solubility, 193
- inverse relationship, 155
- iron-protoporphyrin IX complex, 56
- irreversible binding, 119
- irreversible inhibitor, 83, 84
- itraconazole, 69, 75, 76, 123, 144
- jejunum, 20
- kanamycin, 22
- ketoconazole, 22, 69, 72, 76, 123, 144, 272
- ketoprofen, 22
- kidney, 25, 32, 40, 44–46, 49, 57, 114, 173, 199, 258
- kinetic solubility, 191–193
- K_m , 15, 27, 65, 76, 78, 177
- knock out, 238
- Langendorff preparation, 267–269
- lattice energy, 191, 194
- LC/MS/MS, 73, 74, 119, 120, 147, 152, 153, 177
- LDL. *See* low-density lipoproteins
- leukemia, 155, 265
- liability, 36, 70, 78, 87, 128, 198, 222, 226, 227, 229, 231, 232, 235, 258, 259, 261, 264–266, 273
- library, 125
- ligand-binding domain, 88–90
- lipophilicity, 20, 68, 128, 140, 197–199, 212, 214
- lipoproteins, 22, 23, 138, 142
- liquid chromatography, 73, 119, 123, 147, 177, 192
- liver homogenate, 177
- liver microsome, 59, 60, 66, 67, 70–73, 79, 85, 123, 126, 127, 149, 159, 236
- log P , 111, 188, 198, 212
- long-term, 4, 41, 210
- Loop of Henle, 25, 26
- lopinavir, 69
- low-density lipoproteins (LDL), 142, 200
- lumen, 20, 26
- lungs, 4, 16, 24, 236
- lymphatic drainage, 18
- macrolide antibiotics, 69, 76, 268
- malignancies, 156
- mammalian CYPs, 60
- management, 6, 7, 170, 204, 213, 245
- mass spectrometry, 73, 119, 147, 177, 247
- maximum tolerated dose (MTD), 95, 240, 241
- MCT, 40
- MDR, 40, 47
- mean life span, 173
- mean residence time (MRT), 176
- membrane permeability, 199
- membrane potential, 260–262
- membrane transporters, 43, 45, 199
- meperidine, 153

- mephenytoin, 62, 67, 72
mesenteric blood circulation, 20
metabolic clearance, 4, 126, 144, 171, 176, 178–182
metabolic stability, 112, 125–127, 129, 178, 214
metabolism-dependent inhibition, 82
metabolite identification, 2, 125, 227
metoprolol, 62, 68, 72, 128
Michaelis-Menten, 15, 177
midazolam, 64, 68, 69, 72, 82, 84, 95, 123
mitochondria, 49, 56, 59, 60, 121, 122
mitochondrial cytochrome b5, 59
MLP, 173, 174
monocarboxylate transporter, 40
moxifloxacin, 269–271
mRNA, 12, 41, 47, 48, 87, 89, 91, 96, 227, 247
MRP. *See* multidrug resistance protein
MRT. *See* mean residence time
MTD. *See* maximum tolerated dose
multicompartmental, 16,
multidrug resistance protein (MRP), 40, 46
multiple-dose, 243, 248
mutagenesis, 41, 61, 256
mutagenicity, 222, 224, 225, 228–230
mutation, 42, 44, 46, 47, 61, 62, 225, 228, 239, 256, 264, 265
- NADPH, 57–59, 70, 71, 85, 177
N-alkylation, 69
N-demethylation, 64–66, 73, 94
nephrotoxicity, 144
neurological disease, 48,
neuropathic pain, 49
new chemical entity, 1, 2, 118, 175, 221
nicardipine, 22, 139, 142
nifedipine, 22, 68, 69, 72, 75, 77, 94, 95
N-methyl-D-aspartic acid (NMDA)
 receptor, 156
NMR. *See* nuclear magnetic resonance
noncompartmental, 11, 17, 18
non-GLP, 229, 231, 241
nonoral route of administration, 18
nonspecific binding, 148, 150, 198, 263
non-steroidal antiinflammatory drugs (NSAIDs), 48, 153, 154
N-oxidation, 65
- Noyes-Whitney equation, 190
NSAIDs. *See* non-steroidal antiinflammatory drugs
NTCP, 40
N-tert-butyl isoquine, 172
nuclear magnetic resonance (NMR), 145, 247
nuclear receptor, 55, 87, 88, 90, 232
nucleoside transporter, 40
nucleotide, 39, 43, 47, 57, 59, 177, 228
- OAT1, 41–45, 47, 48
OAT3, 43, 45, 47, 48,
OAT4, 40–43, 45
OATP, 40
OCT, 40, 42, 43, 49
OCTN, 40, 49
off-target effect, 3, 239, 242
oligomerization, 41, 44, 45
omeprazole, 62, 65, 67, 68, 94, 131
oncology, 1, 240
one-compartment, 16
oral absorption, 19, 196, 198, 200
oral bioavailability, 3, 28, 34, 49, 124, 125, 128, 146, 195, 198, 213
oral formulation, 20, 28, 36, 37
organic anion transporter, 40, 44, 46, 48
organic cation transporter, 40, 42
organizational model, 6
overdose, 76
oxidation degradation, 202
oxyphenbutazone, 130, 140
- parallel tube model, 179
parental formulation, 189
particle size distribution, 188
particle size reduction, 190, 196
patch clamp, 232, 234, 256, 259, 261, 262, 264
patent, 5
penetration, 4, 16, 33, 143
penicillins, 48, 140
peptide transporter, 26, 40
permeability, 4, 15, 22, 34, 35, 145, 187–190, 197–200, 212–213
p-glycoprotein, 20, 26, 34, 42, 95, 199
pharmaceutical development, 3, 6, 170, 185

- pharmaceutical industry, 1, 71, 74, 77, 110, 125, 131, 188, 238, 269
 pharmaceuticals, 3, 187
 pharmacodynamics (PD), 13, 242, 247
 pharmacokinetic (PK) modeling, 24
 pharmacokinetics, 2, 3, 11–13, 15, 30, 31, 48, 135, 136, 142, 169, 172, 190, 242
 preclinical, 2
 pharmacological activity, 24, 25, 29, 36
 pharmacophore, 256, 257, 259
 phase I metabolism, 23, 130
 phase II metabolism, 24, 26, 130
 phase II metabolizing enzymes, 25
 phenacetin, 66, 72–74, 114
 phenylbutazone, 93, 140, 159
 phenytoin, 31, 62, 66, 67, 90, 92, 93, 95, 96, 114, 140, 153, 211
 phospholipidosis, 113, 223, 226
 photostability, 201–203
 physical characterization, 3
 physicochemical property, 205
 physiologic similarity, 236
 piperacillin, 155
 pK_a , 111, 139, 143, 187, 188, 193, 195, 196–198, 212, 214
 placenta, 40, 45, 49
 plasma–protein binding, 2, 30, 31, 34–36, 78, 81, 126, 136, 137, 143–145, 152, 154–156, 160, 178, 198, 270
 plasma proteins, 25, 138, 142, 143, 147, 149, 178
 polarized light microscopy, 195, 205
 polymorphism, 39, 45–48, 50, 55, 62, 66, 69, 141, 180, 203, 204, 208, 210, 212
 polypeptide, 40–42, 44
 poor metabolizer, 62, 66, 67, 94
 population, 2, 3, 42, 62, 66, 68, 122, 141, 156, 180, 200, 228, 262, 264
 porphyrine ring, 69
 portal vein, 19, 24, 27, 79, 179
 portfolio decision, 2
 postcandidate selection, 271
 post-translational modification, 41, 247
 potassium
 channels, 255, 261
 current, 76, 225, 254
 potentiometric method, 192–193
 powder X-ray diffraction, 194, 205–206
 preclinical development, 11, 223, 224, 227, 237, 241, 243–246, 248
 preclinical pharmacokinetics, 2
 preclinical species, 3, 22, 34, 35, 123, 156, 157, 159, 172, 180, 242
 prediction of clearance, 32, 174
 predictive toxicology, 223, 224, 232, 233, 245, 247
 pregnane X receptor, 88, 89
 primary culture, 45, 91, 126
 probenecid, 48, 140
 prodrug, 76, 187, 190, 210–212
 propranolol, 68
 protease inhibitor, 69, 76, 93, 155
 protein-drug complex, 23
 proton-pump inhibitor, 67, 131
 proximal tubules, 26
 pulmonary tissue, 24. *See also* lungs
 Purkinje fiber, 234, 266, 269
 PXR, 88–93
 pXRD, 191, 205–206, 212

 QSAR, 226, 256
 QT interval, 75, 157, 225, 233, 234, 254, 264, 265–268, 270–272
 QT prolongation, 76, 142, 157, 234, 254, 264–268, 170, 271
 quinidine, 68, 72, 95, 139, 153, 272
 quinine, 42, 118
 quinone, 114–116, 118

 R&D, 1, 2, 17, 181
 rabbit-wedge, 268, 269
 radiolabeled analog, 119
 radiometric assay, 73, 234
 ranitidine, 77
 reabsorption, 26, 49
 reactive metabolite, 69, 82, 86, 113, 115, 116, 118–122, 124, 244
 recombinant DNA, 59
 recombinant enzymes, 70, 71
 reduced metabolites, 23
 reduced nicotinamide adenine dinucleotide phosphate, 57, 177. *See also* NADPH
 reductase, 57–59, 70, 116, 200
 regulatory agencies, 5, 225
 regulatory submission, 74, 233
 relative bioavailability, 20

- renal clearance, 26, 145, 198
renal excretion, 23, 25
repolarization, 225, 233, 254, 255,
266–268, 271, 272
reproductive toxicity, 222, 235
respiratory disease, 1
retentate, 149, 150
reverse transcriptase inhibitor, 155
rifampicin, 86, 90, 92, 93–96, 124
ritonavir, 69, 76, 83, 92, 93, 155
- safety assessment, 2, 3, 6, 157, 170, 196,
221, 243, 245
salt form, 20, 194, 195, 197, 204,
210
saquinavir, 83, 155
SAR, 153, 224–227, 229, 230, 232–234,
240, 243, 256
scale-up, 5, 112, 175, 176
screening cascade, 4–6
secondary binding site, 140
selective inhibitor, 67, 123
selective substrate, 67, 70, 71
semipermeable membrane, 147–150
sequence similarity, 40, 59
SGF. *See* simulated gastric fluid
side-effect, 4,
simulated gastric fluid (SGF), 194,
202
sinusoidal membrane, 144, 145, 179
skin, 12, 18, 19, 114
SLC, 40
small molecules, 2, 61, 68, 200, 224, 226,
227, 229, 236, 237, 239, 242, 249
SNP, 26, 47
solid-state characterization, 194, 212
solid-state stability, 202–203
solvate, 191, 204, 206, 208, 209, 215
SOS chromotest, 229
sparfloxacin, 269, 270, 273
sparteine, 68
steady state, 18, 23, 37, 86, 172, 176, 241,
242, 270
subcutaneous route, 18
subdomain, 138, 140
sulfonamide, 140, 159
sulphaphenazole, 67
sulpiride, 49
supernatant, 177, 192
- surface area, 19, 20, 32, 188, 190, 208
surfactant, 195
- T_{max} , 20, 21, 195
taxol, 68
tazobactam, 155
TdP. *See* Torsade de Pointes
telithromycin, 259, 271
teratogenicity, 114, 222, 223, 235
terfenadine, 72, 76, 77, 96, 113, 123, 157,
233, 256, 266, 269, 271, 272
testosterone, 63, 68, 69, 72, 73
tetraethylammonium, 42
therapeutic window, 3
thermal-humidity stress, 203
thermodynamic affinity constant, 137
thermodynamic solubility, 191
thermogravimetric analysis, 206
thioridazine, 266, 267, 269, 271
tissue distribution, 22, 36, 49, 144
tissue permeability, 22, 35
tissue proteins, 22, 36
tolbutamide, 66, 67, 72, 128, 129, 159
topotecan, 49
Torsade de Pointes (TdP), 157, 225, 233,
234, 253, 254, 266–270, 272, 273
torsadogenic, 255, 265, 266, 268–273
torsemide, 66,
toxicokinetics, 223, 243
trafficking, 42–44, 264, 265
transcriptomics, 223, 245–247
transdermal, 12, 18, 19, 34
transmembrane domain, 43, 256
trapping agent, 118–120
tricyclic antidepressant, 62
trimethadon, 66
troglitazone, 62, 90, 92, 93, 96, 114,
124
troleandomycin, 69
trough concentration, 29
tubular secretion, 25, 26, 48
turbidity, 192, 212
tyrosine kinase inhibitor, 155
- ubiquitination, 41, 42
ultracentrifugation, 146, 147, 151, 152
ultrafiltrate, 149, 150
ultrafiltration, 22, 146, 147, 149, 150,
152

- unbound fraction, 17, 22, 23, 27, 28, 31, 35, 36, 138, 143–146, 148, 152, 156, 159, 160, 179
- urate transporter (URAT), 45–47
- U.S. Food and Drug Administration (FDA), 75–77, 110, 170, 181, 182, 188, 204, 225, 237, 249
- UV/vis absorbance, 193
- V_{area} , 21
- V_c , 21
- V_d , 18, 21, 22, 28–31, 34, 36, 37
- V_{dss} , 18, 21, 22
- V_{max} , 27, 177, 185
- valproic acid, 113, 114, 140, 146
- ventricular arrhythmia, 76
- ventricular fibrillation, 268
- ventricular tachycardia, 157, 225, 268
- ventricular wedge, 268–270
- verapamil, 68, 83, 84, 95, 153, 265, 266, 269, 271, 272
- volume of distribution, 18, 21, 22, 32, 35, 36, 142, 143, 155, 160, 161, 171, 172
- warfarin, 22, 61, 66, 68, 72, 94, 95, 139–141, 153, 159, 160
- well-stirred model, 179
- wild-type, 42, 62, 141, 239
- World Health Organization (WHO), 189
- Xenopus oocytes, 45, 256
- zero-order elimination, 14, 15

